rts logo

New Big Money Means Acadia Pharmaceuticals Inc (ACAD) Investors Could Reap Benefit

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is -1.47% lower on its value in year-to-date trading and has touched a low of $14.15 and a high of $24.27 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ACAD stock was last observed hovering at around $18.26 in the last trading session, with the day’s loss setting it -0.18%.

Currently trading at $18.08, the stock is -5.87% and -1.59% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.56 million and changing -0.99% at the moment leaves the stock 8.29% off its SMA200. ACAD registered -24.70% loss for a year compared to 6-month gain of 9.05%.

The stock witnessed a -2.32% loss in the last 1 month and extending the period to 3 months gives it a 10.78%, and is -4.84% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.63% over the week and 4.08% over the month.

Acadia Pharmaceuticals Inc (ACAD) has around 654 employees, a market worth around $3.02B and $957.80M in sales. Current P/E ratio is 13.30 and Fwd P/E is 19.53. Profit margin for the company is 23.64%. Distance from 52-week low is 27.77% and -25.50% from its 52-week high. The company has generated returns on investments over the last 12 months (29.23%).

The EPS is expected to shrink by -56.79% this year

The shares outstanding are 166.71M, and float is at 165.49M with Short Float at 9.19%.

The top institutional shareholder in the company is BAKER BROS. ADVISORS LP with over 42.88 million shares valued at $696.77 million. The investor’s holdings represent 25.9001 of the ACAD Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 13.71 million shares valued at $222.82 million to account for 8.3206 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 13.71 million shares representing 8.2799 and valued at over $222.75 million, while BLACKROCK INC. holds 7.3194 of the shares totaling 12.06 million with a market value of $196.01 million.

Acadia Pharmaceuticals Inc (ACAD) Insider Activity

A total of 0 insider transactions have happened at Acadia Pharmaceuticals Inc (ACAD) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Kihara James, the company’s PRINCIPAL ACCOUNTING OFFICER. SEC filings show that Kihara James sold 475 shares of the company’s common stock on Feb 24 ’25 at a price of $19.96 per share for a total of $9481.0. Following the sale, the insider now owns 20228.0 shares.

Acadia Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 24 ’25 that Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER) sold a total of 773 shares of the company’s common stock. The trade occurred on Feb 24 ’25 and was made at $19.96 per share for $15429.0. Following the transaction, the insider now directly holds 53882.0 shares of the ACAD stock.

Still, SEC filings show that on Nov 19 ’24, Teehan Brendan (EVP, COO, HEAD OF COMMERCIAL) disposed off 10,329 shares at an average price of $16.81 for $0.17 million. The insider now directly holds 62,105 shares of Acadia Pharmaceuticals Inc (ACAD).

Acadia Pharmaceuticals Inc (ACAD): Who are the competitors?

One of the company’s main competitors (and peers) include Eli Lilly & Co. (LLY) that is trading 19.23% up over the past 12 months.Vanda Pharmaceuticals Inc. (VNDA) lies in the list of competitors of the Acadia Pharmaceuticals Inc and is 31.20% higher over the same period from ACADJohnson & Johnson (JNJ) is 3.63% up on the 1-year trading charts.

Related Posts